



ASX Announcement

24 January 2022

## Investor Briefing - Q2 FY22 Results

**SYDNEY, Australia, Monday 24 January 2022** - Atomo Diagnostics Limited (ASX:AT1) (**Atomo**) advises that it will be releasing its Quarterly Activity Report and Appendix 4C for the quarter ended 31 December 2021 prior to market open tomorrow, Tuesday, 25 January 2022.

Atomo invites investors to attend an online briefing to discuss the results at **11.15 am (Sydney time) on Tuesday, 25 January 2022.**

During the briefing, Co-founder/Managing Director, John Kelly, and Chief Financial Officer, Will Souter, will present an activity update and discuss recent developments. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

[https://us02web.zoom.us/webinar/register/WN\\_ytf8jdJqRIKZiljZxbDy5g](https://us02web.zoom.us/webinar/register/WN_ytf8jdJqRIKZiljZxbDy5g)

Once the registration form is completed, investors will receive a confirmation email with details on how to access the briefing. If you would like to ask a question during the briefing, please send your question ahead of the session to: [george.kopsiaftis@irdepartment.com.au](mailto:george.kopsiaftis@irdepartment.com.au)

For more information, please contact:

Jane Lowe  
IR Department  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
Phone: +61 411 117 774

John Kelly  
Atomo Diagnostics  
[john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
Phone: +61 401 922 279

*This announcement was authorised by the Managing Director.*



### **About Atomo**

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at [www.atomodiagnosics.com](http://www.atomodiagnosics.com).

### **Forward looking statements**

This announcement may contain forward looking statements which may be identified by words such as "believes", "considers", "could", "estimates", "expects", "intends", "may", and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Atomo or its Directors and management, and could cause Atomo's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements